Immupharma (IMM)

 

LSE:IMM: Holding(s) in Company

Immupharma

29 Dec 2016 10:54:57

Immupharma PLC

RNS Number : 9563S
Immupharma PLC
29 December 2016
 

RNS : FOR IMMEDIATE RELEASE

29 DECEMBER 2016

 

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

TR1 NOTIFICATION OF MAJOR INTEREST

 

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Lanstead Capital LP ("Lanstead"). Lanstead's holding in ImmuPharma is now confirmed at a total of 7,421,555 Ordinary Shares which equates to a current position in the Company of 5.95% of the 124,638,362 total voting rights.

 

Full disclosure of the TR1 is shown below:

 

-Ends-

For further information please contact:

 

ImmuPharma plc (www.immupharma.org)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman


Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

        + 44 (0) 7721 413496

 

 

 

Panmure, Gordon & Co., (NOMAD & Broker)

 

+44 (0) 20 7886 2500

Freddy Crossley, Duncan Monteith, Corporate Finance

Charles Leigh-Pemberton, Corporate Broking

 

 

Northland Capital Partners Limited (Joint Broker)

Patrick Claridge, David Hignell, Corporate Finance

Rob Rees, John Howes, Corporate Broking

 

                                                  

 

 

 

+44 (0)20 3861 6631




 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi



1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
ii

Immupharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

x

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


An event changing the breakdown of voting rights


Other      

(please specify):


3. Full name of person(s) subject to the
notification obligation:
iii

Lanstead Capital LP

4. Full name of shareholder(s)
 (if different from 3.):iv


5. Date of the transaction and date on
which the threshold is crossed or
reached:
v

28 December 2016

6. Date on which issuer notified:

28 December 2016

7. Threshold(s) that is/are crossed or
reached:
vi, vii

8%, 7%, 6%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB0033711010

10,521,555

10,521,555

7,421,555

7,421,555


5.95%




B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date
xiii

Exercise/
Conversion Period
xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

N/A






C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period
xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

N/A




 

 

Nominal

Delta




Total (A+B+C)

Number of voting rights

Percentage of voting rights

7,421,555

5.95%

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi

 

N/A


Proxy Voting:

10. Name of the proxy holder:


11. Number of voting rights proxy holder will cease
to hold:


12. Date on which proxy holder will cease to hold
voting rights:




13. Additional information:



14. Contact name:

Lisa De Vargas, Lanstead Partners Limited

15. Contact telephone number:

+1 (801) 895-3700

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBKLFLQLFEFBL